A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer

Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers. Investigators have developed anti-HER2 CAR-modified T cells and validated the efficiency targeting HER2-positive cancer in preclinical studies. This study is aimed to confirm its adverse effects including cytokine storm response and any other adverse effects. In addition, CAR-T cells persistence, tumor elimination and disease status after treatment will be evaluated.

嵌合抗原受体T细胞（Chimeric antigen receptor T cells，CAR-T）疗法在实体瘤领域尚未得到充分探索。人表皮生长因子受体2（Human epidermal growth factor receptor-2，HER2）在多种癌症中广泛表达。研究人员已开发出抗HER2的CAR修饰T细胞，并在临床前研究中验证了其靶向HER2阳性癌症的有效性。本研究旨在确认该疗法的不良反应，包括细胞因子风暴反应及其他各类不良反应。此外，本研究还将评估治疗后CAR-T细胞的存续情况、肿瘤清除效果及患者疾病状态。